In Range

InRange - the first randomised, Phase 4 study to use Time-In-Range (TIR) as the primary endpoint to compare second generation basal insulin analogues Toujeo and insulin degludec 100U/mL in people with T1DM

Time-in-Range Study Design

Watch this 2.30 min video on the InRange^* study design. Alternatively, you can also download the published paper below.

Published study design

^{*The InRange study has been sponsored by Sanofi}

Time in Range Guide

View the guide below to find out more about the impact of time in range on your patients.

View Guide

Always up to date?

Webinars, evidence, expert videos, peer-to-peer events… Do you want to be the first to know when new, relevant information is available? Let us know and we’ll send you a message.

Send me relevant updates

<span style="display: block; margin-top: 60px;">Time to Think<span style="font-size: 0.6em; display: block; margin: 5px 0;">Time in Range</span></span>

InRange - the first randomised, Phase 4 study to use Time-In-Range (TIR) as the primary endpoint to compare second generation basal insulin analogues Toujeo and insulin degludec 100U/mL in people with T1DM

Time-in-Range Study Design

Time in Range Guide

Always up to date?